Serum Osteopontin, KL-6, and Syndecan-4 as Potential Biomarkers in the Diagnosis of Coal Workers’ Pneumoconiosis: A Case–Control Study

References

• Perret JL, Plush B, Lachapelle P, et al. Coal mine dust lung disease in the modern era. Respirology. 2017;22(4):662–670. doi:10.1111/resp.13034
   PubMed Web of Science ®Google Scholar
• Vanhée D, Gosset P, Marquette CH, et al. Secretion and mRNA expression of TNF alpha and IL-6 in the lungs of pneumoconiosis patients. Am J Respir Crit Care Med. 1995;152(1):298–306. doi:10.1164/ajrccm.152.1.7599837
   PubMed Web of Science ®Google Scholar
• Leung CC, Yu IT, Chen W. Silicosis. Lancet. 2012;379(9830):2008–2018. doi:10.1016/s0140-6736(12)60235-9
   PubMed Web of Science ®Google Scholar
• The L. Improving occupational health in China. Lancet. 2019;394(10197):443. doi:10.1016/s0140-6736(19)31799-4
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. The Statistical Bulletin on the development of public health; 2018. Available from: http://www.gov.cn/guoqing/2020-04/29/content_5507528.htm. Accessed April 29, 2020.
   Google Scholar
• Zhang Z, Zhao Y, Sun D. China’s occupational health challenges. Occup Med. 2017;67(2):87–90. doi:10.1093/occmed/kqw102
   Google Scholar
• Chen Z, Shi J, Zhang Y, et al. Screening of serum biomarkers of coal workers’ pneumoconiosis by metabolomics combined with machine learning strategy. Int J Environ Res Public Health. 2022;19(12). doi:10.3390/ijerph19127051
   Web of Science ®Google Scholar
• Liu H, Ma J, Jiang T, et al. Decreased soluble receptor of advanced glycation end product levels correlated with inflammation in silicosis. Mediators Inflamm. 2020;2020:2683753. doi:10.1155/2020/2683753
   PubMed Web of Science ®Google Scholar
• Lee JS, Shin JH, Lee JO, et al. Blood levels of IL-Iβ, IL-6, IL-8, TNF-α, and MCP-1 in pneumoconiosis patients exposed to inorganic dusts. Toxicol Res. 2009;25(4):217–224. doi:10.5487/tr.2009.25.4.217
   PubMedGoogle Scholar
• Pang J, Luo Y, Wei D, et al. Comparative transcriptome analyses reveal a transcriptional landscape of human silicosis lungs and provide potential strategies for silicosis treatment. Front Genet. 2021;12:652901. doi:10.3389/fgene.2021.652901
   PubMed Web of Science ®Google Scholar
• Li J, Liang C, Zhang ZK, et al. TAK1 inhibition attenuates both inflammation and fibrosis in experimental pneumoconiosis. Cell Discov. 2017;3:17023. doi:10.1038/celldisc.2017.23
   PubMed Web of Science ®Google Scholar
• Xue C, Wu N, Li X, Qiu M, Du X, Ye Q. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study. BMC Pulm Med. 2017;17(1):144. doi:10.1186/s12890-017-0489-0
   PubMedGoogle Scholar
• Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107(9):1055–1061. doi:10.1172/jci12980
   PubMed Web of Science ®Google Scholar
• Dong J, Ma Q. Osteopontin enhances multi-walled carbon nanotube-triggered lung fibrosis by promoting TGF-β1 activation and myofibroblast differentiation. Part Fibre Toxicol. 2017;14(1):18. doi:10.1186/s12989-017-0198-0
   PubMedGoogle Scholar
• Hu Y, Wang LS, Jin YP, et al. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients. Clin Respir J. 2017;11(3):337–345. doi:10.1111/crj.12341
   PubMed Web of Science ®Google Scholar
• Chiu YH, Chu CC, Lu CC, et al. KL-6 as a biomarker of interstitial lung disease development in patients with Sjögren syndrome: a retrospective case-control study. J Inflamm Res. 2022;15:2255–2262. doi:10.2147/jir.S352085
   PubMed Web of Science ®Google Scholar
• Jiang D, Xiao H, Dong R, et al. Krebs von den Lungen-6 levels in untreated idiopathic pulmonary fibrosis. Clin Respir J. 2022;16(3):234–243. doi:10.1111/crj.13475
   PubMed Web of Science ®Google Scholar
• Choi S, Chung H, Hong H, et al. Inflammatory hypoxia induces syndecan-2 expression through IL-1β-mediated FOXO3a activation in colonic epithelia. FASEB j. 2017;31(4):1516–1530. doi:10.1096/fj.201601098R
   PubMed Web of Science ®Google Scholar
• Cassinelli G, Zaffaroni N, Lanzi C. The heparanase/heparan sulfate proteoglycan axis: a potential new therapeutic target in sarcomas. Cancer Lett. 2016;382(2):245–254. doi:10.1016/j.canlet.2016.09.004
   PubMed Web of Science ®Google Scholar
• Luo Q, Ning P, Zheng Y, Shang Y, Zhou B, Gao Z. Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study. Crit Care. 2018;22(1):15. doi:10.1186/s13054-018-1943-y
   PubMedGoogle Scholar
• Agere SA, Kim EY, Akhtar N, Ahmed S. Syndecans in chronic inflammatory and autoimmune diseases: pathological insights and therapeutic opportunities. J Cell Physiol. 2018;233(9):6346–6358. doi:10.1002/jcp.26388
   PubMed Web of Science ®Google Scholar
• Götte M. Syndecans in inflammation. FASEB j. 2003;17(6):575–591. doi:10.1096/fj.02-0739rev
   PubMed Web of Science ®Google Scholar
• Tanino Y, Wang X, Nikaido T, et al. Syndecan-4 inhibits the development of pulmonary fibrosis by attenuating TGF-β signaling. Int J Mol Sci. 2019;20(20):4989. doi:10.3390/ijms20204989
   PubMed Web of Science ®Google Scholar
• Toba-Ichihashi Y, Yamaoka T, Ohmori T, Ohba M. Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells. Biochem Biophys Rep. 2016;5:1–7. doi:10.1016/j.bbrep.2015.11.021
   PubMedGoogle Scholar
• Brazil DP, Church RH, Surae S, Godson C, Martin F. BMP signalling: agony and antagony in the family. Trends Cell Biol. 2015;25(5):249–264. doi:10.1016/j.tcb.2014.12.004
   PubMed Web of Science ®Google Scholar
• Murphy N, Gaynor KU, Rowan SC, et al. Altered expression of bone morphogenetic protein accessory proteins in murine and human pulmonary fibrosis. Am J Pathol. 2016;186(3):600–615. doi:10.1016/j.ajpath.2015.10.032
   PubMed Web of Science ®Google Scholar
• Koli K, Myllärniemi M, Vuorinen K, et al. Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol. 2006;169(1):61–71. doi:10.2353/ajpath.2006.051263
   PubMed Web of Science ®Google Scholar
• Myllärniemi M, Lindholm P, Ryynänen MJ, et al. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177(3):321–329. doi:10.1164/rccm.200706-945OC
   PubMed Web of Science ®Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805
   PubMed Web of Science ®Google Scholar
• Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979;16(4):885–893. doi:10.1016/0092-8674(79)90103-x
   PubMed Web of Science ®Google Scholar
• Lamort AS, Giopanou I, Psallidas I, Stathopoulos GT. Osteopontin as a link between inflammation and cancer: the thorax in the spotlight. Cells. 2019;8(8):815. doi:10.3390/cells8080815
   PubMed Web of Science ®Google Scholar
• Gela A, Bhongir RK, Mori M, et al. Osteopontin that is elevated in the airways during COPD impairs the antibacterial activity of common innate antibiotics. PLoS One. 2016;11(1):e0146192. doi:10.1371/journal.pone.0146192
   PubMed Web of Science ®Google Scholar
• Hetman O, Krakhmalova E, Radzishevska Y. The diagnostic value of osteopontin as an early marker of pulmonary hypertension affected by chronic obstructive pulmonary disease and concomitant ischemic heart disease. Georgian Med News. 2018;2018:41–447.
   Google Scholar
• Morimoto Y, Hirahara K, Kiuchi M, et al. Amphiregulin-producing pathogenic memory T helper 2 cells instruct eosinophils to secrete osteopontin and facilitate airway fibrosis. Immunity. 2018;49(1):134–150.e6. doi:10.1016/j.immuni.2018.04.023
   PubMed Web of Science ®Google Scholar
• Dong J, Ma Q. Myofibroblasts and lung fibrosis induced by carbon nanotube exposure. Part Fibre Toxicol. 2016;13(1):60. doi:10.1186/s12989-016-0172-2
   PubMed Web of Science ®Google Scholar
• Mercer RR, Scabilloni JF, Hubbs AF, et al. Distribution and fibrotic response following inhalation exposure to multi-walled carbon nanotubes. Part Fibre Toxicol. 2013;10:33. doi:10.1186/1743-8977-10-33
   PubMed Web of Science ®Google Scholar
• White ES, Xia M, Murray S, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2016;194(10):1242–1251. doi:10.1164/rccm.201505-0862OC
   PubMed Web of Science ®Google Scholar
• Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun. 2005;338(4):1845–1852. doi:10.1016/j.bbrc.2005.10.144
   PubMed Web of Science ®Google Scholar
• Wang J, Zheng P, Huang Z, et al. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features. BMC Pulm Med. 2020;20(1):315. doi:10.1186/s12890-020-01336-y
   PubMed Web of Science ®Google Scholar
• Xue M, Cai C, Zeng Y, et al. Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features. Medicine. 2021;100(4):e24260. doi:10.1097/md.0000000000024260
   PubMed Web of Science ®Google Scholar
• Nikaido T, Tanino Y, Wang X, et al. Serum syndecan-4 as a possible biomarker in patients with acute pneumonia. J Infect Dis. 2015;212(9):1500–1508. doi:10.1093/infdis/jiv234
   PubMed Web of Science ®Google Scholar
• O’Reilly S. Circulating Gremlin-1 is elevated in systemic sclerosis patients. J Scleroderma Relat Disord. 2021;6(3):286–289. doi:10.1177/23971983211036571
   PubMed Web of Science ®Google Scholar
• Aoshima Y, Enomoto Y, Muto S, et al. Gremlin-1 for the differential diagnosis of idiopathic pulmonary fibrosis versus other interstitial lung diseases: a clinical and pathophysiological analysis. Lung. 2021;199(3):289–298. doi:10.1007/s00408-021-00440-y
   PubMed Web of Science ®Google Scholar